60 results about "Hypersensitivity Diseases" patented technology

The invention belongs to the technical field of preparation of probiotics, and provides a bacterial strain with anti-allergic and immunity-improving effects and application of the bacterial strain. According to the method, a three-layer physical self-assembly structure is adopted, and polysaccharide-polyphenol layer-by-layer self-assembly coating treatment, lipid insertion layer treatment and calcium ion crosslinking protection coating treatment are sequentially carried out. And mannan oligosaccharide MOS and / or galactooligosaccharide GOS are / is mixed in the chitosan layer in a ratio of 0.05-0.15% w / v, and the surface sugar ligand density reaches 4-8 [mu] g per 10 CFU. The coating is constructed under the condition that the pH value is 5.4-5.8; the thickness of the lipid layer is 20-80 nm when the pH value is 5.6-6.2; the cross-linked layer is treated at the pH of 6.0-6.5, so that the gastric acid environment is stable for 2 hours, and the gastric acid is controllably released in intestinal juice for 2-4 hours. The prepared strain has the total thickness of 220-900 nm, the outermost layer coverage rate is larger than or equal to 85%, the gastric juice survival rate is remarkably improved, the strain can be prepared into an oral preparation to be used for preventing and relieving allergic diseases, the viable count of each dose is 1 * 10 <-1 > * 10 <-1 > CFU, and the process is mild and suitable for industrial production.

Aspects of the application provide anti-IL-13 antibodies and methods of using the same in treating IL-13-mediated diseases (e.g., allergic disease or other inflammatory diseases).

Disclosed is a polypeptide dimeric protein containing two monomers, each of which contains an extracellular domain (FcεRIa-ECD) of an alpha subunit of an IgE Fc receptor. The dimeric protein has advantages that an excellent binding ability to IgE is exhibited as compared with a conventional therapeutic agent containing an anti-IgE antibody, and less other side effects are exhibited due to lack of ADCC and CDC functions. Thus, the dimeric protein can be applied to a medical product for treating or preventing an IgE-mediated allergic disease.

TSLP-TRAPs are a novel class of biologics that have been developed to inhibit the activity of TSLP. By binding to TSLP, TSLP-TRAPS effectively block the interaction between TSLP and its receptor, preventing downstream signaling and immune cell activation. This makes TSLP-TRAPs an attractive therapeutic option for a variety of inflammatory and allergic diseases, including asthma, atopic dermatitis, and eosinophilic esophagitis.

The application relates to the field of biological medicine, and discloses application of folic acid in prevention, diagnosis and treatment of genetic, infectious or allergic diseases. The application finds that the folic acid can achieve the prevention and treatment effects on the genetic, infectious or allergic diseases by improving inflammation, regulating iron ion metabolism, correcting intestinal flora disorder, reducing liver / intestinal tissue damage, inhibiting expression of inflammatory factors and promoting expression of Nox2. Meanwhile, the application provides application of one or more of the folic acid, S100a8, S100a9, Nox2 and IFN-gamma as a diagnostic or auxiliary diagnostic marker of biliary atresia. Meanwhile, the application provides the folic acid or a derivative thereof, which is prepared into food, a nutritional preparation or a medicine and applied to children or adults, so as to achieve the purposes of preventing and treating biliary atresia, cholangitis, jaundice, infectious diseases, intestinal diseases and diseases caused by abnormal folic acid metabolism.

The invention relates to a gene therapy vector nucleic acid construct for allergic diseases and a use method of the gene therapy vector nucleic acid construct. In particular to an expression cassette, the expression cassette comprises the following elements: a promoter, an optional first signal peptide coding sequence, a heavy chain coding sequence of an anti-IgE antibody, an optional linker sequence, an optional second signal peptide coding sequence and a light chain coding sequence of the anti-IgE antibody, and the invention also provides an adeno-associated virus vector containing the expression cassette. The gene expression framework of the adeno-associated virus vector can realize high-level expression of a target gene, and can be used for treating allergic diseases such as allergic asthma and chronic spontaneous urticaria.

The invention belongs to the technical field of biological medicines, and particularly relates to application of chenodeoxycholic acid in preparation of drugs for treating allergic diseases. It is found that CDCA can effectively inhibit pyroptosis and secretion of proinflammatory factors, expression of complement inhibition proteins CD46, CD55 and CD59 is remarkably up-regulated, expression of the complement inhibition proteins CD46, CD55 and CD59 is finally promoted, and occurrence and development of allergic diseases are effectively relieved. In a mouse model, CDCA can significantly improve OVA-induced food allergy symptoms, and has application prospects in treatment of allergic diseases.

The present invention relates to a DcR3 variant, DNA encoding the DcR3 variant, a vector containing the DNA, a transformant obtained by introducing the vector, a method for producing a variant using the transformant, and a prophylactic or therapeutic agent for an autoimmune disease, an inflammatory disease or an allergic disease comprising the variant as an active ingredient. The present invention relates to a DcR3 variant having binding activity (preferably neutralizing activity) against a ligand of DcR3 while showing reduced production of aggregates and / or improved in vivo kinetics compared to wild-type DcR3 when prepared with a mammalian-derived cell as a host, and provides a DcR3 variant comprising a portion of DcR3 and a portion of a TNF superfamily molecule.

The invention discloses a multilayer nanofiber oral paste loaded with an allergen-immunologic adjuvant composition as well as a preparation method and application of the multilayer nanofiber oral paste. The multilayer nanofiber oral paste has an adhesion function. The multilayer nanofiber oral paste is prepared by adopting a continuous electrostatic spinning technology, the adhesion layer is prepared from a polymer material, and the backing layer is prepared from a hydrophobic polymer material. The invention relates to an allergen-immunologic adjuvant composition, and the allergen-immunologic adjuvant composition or a composition nanoparticle is loaded by an adhesive layer. The multi-layer nanofiber oral paste is applied to an oral mucosa area of a patient within a treatment course, so that long-acting release of allergens is realized. After the multi-layer nanofiber oral paste is repeatedly used by a patient, the prevention or treatment of allergic diseases (allergic diseases) can be realized.

1. The name of the design product: bioelectromagnetic physical therapy instrument. 2. The use of the design product: the design product is used for the auxiliary treatment of allergic diseases. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The present invention relates to treatment and prevention of allergic diseases and, specifically, to an allergic disease immunomodulation method, which suppresses SIRT7 of nasal cavity epithelial cells to inhibit allergy mediators. The present invention suppresses SIRT7 of nasal cavity epithelial cells to inhibit the secretion of epithelial cell cytokines (TSLP), which recognize allergens to attract immune cells that induce an immune response, so that high-level processes of allergic reactions are blocked, and thus allergic diseases can be fundamentally treated and prevented.

The present invention relates to compounds of formula (I) with STAT6 inhibitory activity for use in methods of treatment of inflammatory or allergic diseases, such as e.g. atopic dermatitis.

This invention provides a small molecule inhibitor targeting the FcεRIγ subunit and its application. It discovers that erythrophenol can act as a small molecule inhibitor targeting the FcεRIγ subunit, thereby inhibiting the occurrence of allergic reactions. This invention confirms the direct binding interaction between erythrophenol and the FcεRIγ subunit using SPR and CETSA techniques, revealing that erythrophenol can target and inhibit the FcεRIγ subunit. Furthermore, this invention finds that erythrophenol can significantly inhibit the release of IgE signal-induced β-aminoglycosidase in mast cells, exhibiting a significant ability to inhibit IgE signal-mediated mast cell degranulation and suppress mast cell activation-mediated allergic reactions. This fully demonstrates that erythrophenol, as an inhibitor targeting the FcεRIγ subunit, holds promise as the first inhibitor to induce FcεRIγ subunit degradation in anti-type I allergic diseases, and has broad application prospects for further use in anti-allergy treatment.

The invention belongs to the technical field of immunotherapy of allergic diseases, and provides a method for identifying dominant B cell epitopes and T cell epitopes in wheat omega-5 prolamin. According to the identification method provided by the invention, an immunoinformatics tool, a proliferation test, a degranulation test and the like are comprehensively applied, and the cell proliferation capacity, cell factor release, IgG / IgE binding capacity and degranulation capacity of T / B cell epitopes are evaluated. Results show that the T cell epitopes T1 and T2 sharing the same sequence are relatively strong in multiplication capacity, can up-regulate Th2 related cell factors, but do not have degranulation activity. Three B cell peptide fragments B3, B4 and B9 which share a common motif region QQXPQQQ (X = F, L) can promote IgG / IgE binding and degranulation capabilities. These findings would contribute to the development of epitope-based immunotherapies against wheat allergy individuals.

The application discloses a traditional Chinese medicine composition for treating allergic diseases, which is prepared from the following traditional Chinese medicines in parts by weight: 10-30 parts of raw astragalus, 5-15 parts of dark plum, 5-15 parts of rinkhale, 10-25 parts of small red bean, 5-15 parts of white flag, 5-15 parts of medlar, 5-15 parts of angelica, 5-15 parts of mulberry leaf, 5-15 parts of dried tangerine or orange peel, and 3-10 parts of honey. The preparation method and application of the traditional Chinese medicine composition are also disclosed. The traditional Chinese medicine composition has the functions of benefiting qi and nourishing blood, dispelling wind and dampness, clearing heat and promoting diuresis, and regulating liver and spleen. The traditional Chinese medicine composition is proved to have the function of treating allergic diseases through systematic pharmacological experiments. The components of the traditional Chinese medicine composition are all medicinal and edible materials, and the traditional Chinese medicine composition is expected to be developed into a new medicine or functional food for effectively preventing and treating allergic diseases, and has good clinical significance.

The present application relates to a kind of chimeric protein PA508 and its application, belong to the prevention, diagnosis and desensitization treatment technical field of allergic disease. The fusion polypeptide of the present application is named as chimeric protein PA508, the amino acid sequence of the fusion polypeptide is as shown in SEQ ID NO:1. The fusion polypeptide of the present application includes the allergen characteristic peptide from different species, so cross-species immune response can be realized, can prevent or treat the allergic reaction caused by allergen from animal and allergen from plant.

The application discloses a sesquiterpene derivative, a preparation method and application thereof. The application provides a novel sesquiterpene derivative which is obtained by modifying atractylodin III. Activity research shows that the sesquiterpene derivative has stronger inhibiting effect on IgE or histamine secretion than atractylodin III. It is known to those skilled in the art that allergy is mediated by IgE, and histamine secretion under the stimulation of IgE is an important cause of various allergic symptoms. Therefore, the sesquiterpene derivative provided by the application has the prospect of being developed into a medicine for preventing and / or treating diseases which are prevented and / or treated by inhibiting IgE or histamine secretion, such as allergic diseases like food allergy.

The invention relates to Interleukin-2 (IL-2) variants for the prevention or treatment of immune disorders, including with no limitations allergic, autoimmune, chronic or acute inflammatory and infectious diseases; graft-versus-host disease; graft rejection and cancer. The invention also relates to the use of said IL-2 variants for the screening of anti-IL-2 antibodies with pro-T-effector or pro-T-regulatory cell activity.

The invention discloses an application of N-(4-methoxyphenyl)-4-(4-methoxyphenyl) benzenesulfonamide in preparation of drugs for treating allergic diseases, and belongs to the technical field of biological medicines. The invention discloses a new pharmaceutical application of N-(4-methoxyphenyl)-4-(4-methoxyphenyl) benzenesulfonamide for the first time, and the N-(4-methoxyphenyl)-4-(4-methoxyphenyl) benzenesulfonamide serving as an anti-allergic antagonist can effectively inhibit phospholipase C activity of stimulated cells and mediated calcium mobilization thereof in vitro. And the effective dose of the desloratadine, which is a positive drug, is lower in vivo to generate a comparable anti-allergic effect with the desloratadine. Meanwhile, in animal models of allergic rhinitis and atopic dermatitis, compared with a positive drug desloratadine, the compound can effectively inhibit the pathological progress of diseases at a lower dosage. Therefore, the compound has a definite effect of inhibiting in-vitro and in-vivo anaphylaxis, and can be effectively applied to the development of drugs for treating allergic diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a compound in preparation of an anti-allergic medicine. The degranulation inhibition effect is verified through a mast cell in-vitro culture model, the overall anti-allergic activity is verified by combining an animal allergy model, and a series of experiments prove that the compound A33 can inhibit I-type anaphylaxis (such as ear and subcutaneous anaphylaxis) mediated by an IgE antibody. Different from a traditional anti-allergic drug (such as an antihistamine drug), the compound A33 is used for preventing release of media such as TNF-alpha and IL-6 from the source in an anaphylactic reaction starting link that the compound A33 directly inhibits mast cell degranulation in allusion to downstream blocking of an allergic medium, so that the compound A33 is introduced into the field of anti-allergic product research; a new candidate strategy with a clear targeting mechanism and an experimental basis is provided for prevention and / or treatment of allergic diseases, and the application value in anti-allergic drugs, cosmetics or daily chemical products is wide.

The present application addresses the problem of providing a regulatory T cell induction promoter containing D-sorbose and / or D-allose as an active ingredient. The problem is solved by providing a regulatory T cell induction promoter containing D-sorbose and / or D-allose as an active ingredient.

The invention provides compounds of Formula (I), and pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as inhibitors of STAT family members, and methods for using such compounds to treat, ameliorate or prevent an inflammatory disease or allergic disease, including asthma and atopic dermatitis associated with STAT proteins, especially associated with IL-4 signaling.

Compositions and methods for treating diseases and conditions mediated by the high affinity IgE receptor (FcεRI) are provided. Also provided are antisense oligomers for modulating splicing of mRNA encoding a MS4A6A protein, optionally in addition to antisense oligomers for modulating splicing of mRNA encoding the FcεRIβ protein, thereby down-regulating cell-surface expression of FcεRI, and uses of the antisense oligomers for inhibiting mast cell degranulation, cytokine release, migration, and proliferation; for inhibiting anaphylaxis reactions in individuals, for treating allergic conditions in individuals, for reducing the incidence of allergic reactions in individuals, for treating individuals at risk of developing anaphylactic reactions, and for treating mast cell-related diseases in individuals.

The application discloses a polypeptide pka15 with immunoregulation efficacy and application thereof. The polypeptide pka15 provided by the application has immunoregulation efficacy, can significantly reduce the number of macrophages and neutrophils at an inflammation site, and can be used for preparing a medicine for relieving and / or treating autoimmune diseases and allergic diseases caused by inflammation. Meanwhile, the polypeptide pka15 can significantly improve the symptoms of IBD, has the efficacy of improving damage to a digestive tract mucosa, can be used for preparing a medicine for relieving and / or treating inflammatory bowel disease and a medicine for protecting and / or repairing damage to the digestive tract mucosa, can be synthesized by a biological or chemical method, is easy to be prepared in a large amount, has simple synthesis, can be prepared into a polypeptide preparation, is convenient for subsequent clinical application and popularization, has no toxic side effects, has better safety as compared with existing glucocorticoid and non-steroidal immunoregulation medicines, and has low medicine cost and good curative effect.

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating allergic rhinitis and allergic dermatitis, a traditional Chinese medicine preparation and a preparation method. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: Shouwuteng 1000-2000 parts, Digupi 1000-2000 parts, Baijianpi 800-1600 parts, Baizhi 600-1800 parts, Kuanfenghua 300-1100 parts, Jinyinhua 300-700 parts, Yekuhua 200-800 parts, Huaihua 400-600 parts and Gancao 400-1000 parts. The nine traditional Chinese medicine raw materials of the traditional Chinese medicine composition are used as monarch, minister, assistant and envoy, and the nine medicines are used together to achieve the effects of cooling blood and detoxifying, nourishing blood and dispelling evil, dispelling wind and relieving itching, and promoting lung and descending qi. Pharmacological experiments show that the formula can significantly reduce inflammatory factors in blood of allergic dermatitis mice, and the effect is good. In addition, the optimal extraction process of the nine medicines is selected, the preparation process is researched, the types and the optimal ratio of the excipients are investigated, and the experimental basis can be provided for hospital preparation registration, so that the traditional Chinese medicine composition can serve allergic disease patients such as AD and AR as early as possible.

The application discloses a microorganism marker composition of an allergic population based on enterotype typing and application thereof in preparation of a reagent or kit for identifying allergic diseases. The application also discloses a kit for identifying allergic diseases. The application further discloses a method for constructing an allergic prediction model based on enterotype typing and application thereof in construction of a system for judging allergic risks of samples. The application first proposes an allergic prediction model based on enterotype stratification, classifies samples through enterotype typing, and then predicts allergic risks of the samples by using corresponding machine learning models. The application can detect allergic risks of children by a non-invasive and non-intrusive method, and only needs feces of the children. The application provides a new technical basis for future research on allergic diseases of children and a new non-invasive and non-intrusive method for detection of allergic diseases of children.

The present invention discloses a crystalline form of a compound, as well as its preparation and use. The compound has the structure shown in Formula I. The crystalline form has relatively good solid-state stability and flowability, relatively low hygroscopicity, and relatively good solubility, making it advantageous for the preparation and storage of pharmaceutical formulations. Furthermore, the crystalline form has excellent pharmacokinetic properties, relatively excellent safety during repeated administration, and can be administered via multiple administration routes (e.g., injection, oral administration). It is available in a wide range of formulations, and has particularly high oral bioavailability, making it highly valuable for practical applications. The crystalline form can be used as a JAK inhibitor to develop drugs for the prevention and / or treatment of inflammatory diseases, tumors, autoimmune diseases, and allergic diseases in humans and / or animals. [Formula 1] JPEG2025542332000054.jpg45170

The invention relates to the technical field of data processing, in particular to a system and a method for auxiliary analysis of hormone-sensitive chronic cough, and the method comprises the following steps: collecting target indexes of a patient, including allergic disease history, sour regurgitation heartburn symptom, hematophilic granulocyte count, CRP, IgE, FEV1 / FVC and FeNO; preprocessing the target index to obtain a preprocessed index; and generating a risk score corresponding to the hormone-sensitive chronic cough according to the pretreatment index. In order to solve the problems that in the prior art, hormone-sensitive cough diagnosis indexes need to depend on a complex detection instrument to be collected, and implementation is difficult, on the basis of regression analysis, the indexes of auxiliary analysis are determined to be clinical data which can be obtained easily based on clinical symptoms, blood routine indexes, lung function examination and the like of a patient, and the hormone-sensitive cough diagnosis indexes are obtained. And a related auxiliary analysis system is established, so that complex instruments required in the traditional medical examination process are omitted, and the medical examination process can be quickly completed in any level of medical institutions.

The invention relates to a fluorescent probe applied to hypochlorous acid detection of allergic diseases as well as a preparation method and application of the fluorescent probe, and belongs to the field of fluorescent probes. The preparation method of the probe comprises the following steps: mixing 1, 3-indandione and 6-(dimethylamino)-naphthaldehyde with an organic solvent, carrying out a condensation reaction under the catalysis of a basic catalyst and under the heating reflux condition of 60-100 DEG C, and treating after the reaction is finished to obtain the fluorescent probe with the structure shown in the formula (I). The fluorescent probe prepared by the invention is high in specificity, strong in anti-interference capability, good in selectivity to hypochlorite ions, good in cell membrane penetrability and biocompatibility, capable of entering living cells in a lossless manner and relatively low in toxicity; the hypochlorous acid concentration (chemical signal) in inflammatory cells can be detected, the viscosity change (physical microenvironment) in the inflammatory cells can also be detected, the dual-function effect is achieved, and a powerful tool is provided for studying the pathological process of allergic diseases.

4-aminoimidazoquinoline compounds and their use are described. The compounds of the invention are dual agonists of Toll-like receptors 7 (TLR7) and TLR8, which induce the expression of IL-12 and IP-10 without over-inducing IL-6. These dual TLR7 / 8 agonists are potentially useful drugs as immune response modifiers. The use of a compound or a salt thereof, according to the invention, in the manufacture of a medicament for the treatment of a disease or condition in which activation of TLR7 and / or TLR8 provides a benefit in a subject in need is described. A compound or pharmaceutical composition for the treatment of a viral infection, cancer, and / or an allergic disease, or for the activation of effective immune responses against a viral infection, a tumor, and / or an allergic disease in a subject in need, is also described.